Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Receivables - Other (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Receivables - Other for 6 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Other changed 0.0% to $1.5 million in Q4 2025 year-over-year; TTM through Nov 2025 was $1.5 million, a 0.0% change, with the full-year FY2025 number at $1.5 million, changed 0.0% from a year prior.
  • Receivables - Other was $1.5 million for Q4 2025 at Nurix Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $7.0 million in Q1 2025 to a low of $600000.0 in Q2 2024.
  • A 5-year average of $2.4 million and a median of $1.6 million in 2024 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: crashed 88.0% in 2021, then surged 445.45% in 2023.
  • Nurix Therapeutics' Receivables - Other stood at $900000.0 in 2021, then rose by 11.11% to $1.0 million in 2022, then skyrocketed by 300.0% to $4.0 million in 2023, then tumbled by 62.5% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Receivables - Other are $1.5 million (Q4 2025), $1.7 million (Q3 2025), and $1.7 million (Q2 2025).